Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neurogene Inc. - Common Stock
(NQ:
NGNE
)
24.91
+5.23 (+26.58%)
Streaming Delayed Price
Updated: 1:39 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
965,543
Open
22.96
Bid (Size)
24.81 (200)
Ask (Size)
25.01 (100)
Prev. Close
19.68
Today's Range
20.50 - 26.40
52wk Range
6.875 - 37.27
Shares Outstanding
42,425,071
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Which stocks are moving on Friday?
↗
Today 12:30 EST
Via
Chartmill
Why Did NGNE Stock Surge 25% In Pre-Market Today?
↗
Today 7:40 EST
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.
Via
Stocktwits
Performance
YTD
+23.6%
+23.6%
1 Month
+25.4%
+25.4%
3 Month
+18.2%
+18.2%
6 Month
+32.2%
+32.2%
1 Year
+44.8%
+44.8%
More News
Read More
Wondering what's happening in today's after-hours session?
↗
February 26, 2026
Via
Chartmill
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
February 26, 2026
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in Upcoming Investor Conferences
February 05, 2026
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2026
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
January 12, 2026
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
November 13, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
November 12, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
November 06, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2025
From
Neurogene Inc.
Via
Business Wire
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
↗
November 04, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 09, 2025
Via
Benzinga
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
October 09, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 08, 2025
From
Neurogene Inc.
Via
Business Wire
4 Biotech Stocks Seeing Explosive Momentum Gains
↗
October 07, 2025
Via
Benzinga
Topics
ETFs
Stocks
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From
Neurogene Inc.
Via
Business Wire
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
↗
September 04, 2025
Via
Benzinga
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
August 11, 2025
From
Neurogene Inc.
Via
Business Wire
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
↗
August 11, 2025
Via
Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Neurogene Inc.
Via
Business Wire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
↗
July 30, 2025
Via
Benzinga
Frequently Asked Questions
Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 24.91
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 02/27/26 01:39 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 1.06B
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
